O16 A study examining the reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: challenges and insights for future clinical trial design
A. Herrick,K. Chakravarty,C. Roberts,J. Pauling,L. Parker,S. Guiducci,A. Prabu,M. Hughes,J. Ravenscroft,S. Dubey,V. Ong,M. Bhushan,C. Rogers,A. Tracey,L. Muir,C. Denton
DOI: https://doi.org/10.1093/RHEUMATOLOGY/KEY075.198
2018-04-01
Abstract:warranted to determine the clinical utility of hsTnI and CMR-ECV in providing risk stratification for arrhythmias and thus refine patient selection for pre-emptive ILR insertion. Background : The reliability of clinician grading of systemic sclerosis (SSc)-digital ulcers (DUs) has been reported to be poor to moderate at best, which is a major concern in clinical trial design. The aim of this study was to examine the reliability of new proposed UK Scleroderma Study Group (UKSSG) DU definitions (no ulcer, healed ulcer and DU) amongst UK for and A of unique 230 image were obtained. For intra-rater reliability, across all of the rater) the overall weighted kappa coefficient was high and was moderate (0.55) when averaged across all individual raters. Overall inter-rater reliability was poor Intra-rater reliability was high for both the dichotomised analyses of preventative ( k ¼ 95% ¼ and treatment ( k ¼ 95% CI ¼ analysis. Inter-rater reliability was fair for the dichotomised analyses of preventative ( k ¼ 0.25, 95% CI ¼ 0.19 -0.31) and moderate for treatment ( k ¼ 0.41, 95% CI ¼ 0.33 0.49) analysis. rating as an outcome measure in clinical trials, including examining the role for objective measurement techniques, centralised image analysis and the development of novel approaches such as the development patient reported outcome instruments for assessing SSc-DU. Disclosures : The authors have declared no conflicts of interest. Background : In systemic sclerosis (SSc) Th2 cytokines provide a possible mechanistic link between autoimmunity and the fibrotic pathology seen. IL-31 is a recently described Th2 cytokine which signals via the oncostatin M receptor/IL-31RA dimer. We sought to determine whether IL-31 is elevated in SSc plasma or blister fluid (BF), and test whether the IL-31RA is expressed by cells relevant to the disease process. The fibrogenic potential of IL-31 was evaluated in a mouse model. Methods : IL-31 was measured by ELISA of plasma and BF (SSc n ¼ 44, HC n ¼ 27). IL-31RA mRNA was assayed by qPCR of SSc and HC fibroblasts, epidermal tissue extracts, and fat derived MSCs. Responses of target cells to IL-31 were measured by next generation sequencing (NGS), migration assays, qPCR and Western blotting. IL- 31 (200ng/day) was delivered by subcutaneous minipump with or without TGFbeta (800ng/day), or saline control for 14 days in wild type Balb/c mice (6-7 per group). Results : Plasma IL-31 was elevated in SSc (HC range 0-792pg/ml, mean 196, SEM 48, SSc range 0-17764, mean 1370, SEM 567, p < 0.048). BF IL-31 trended towards elevation in SSc
Medicine